life support system News
-
Micropore, Inc. 2020 Champion of Maryland Manufacturing
SCALING PRODUCTION IN RESPONSE TO THE CHALLENGES OF COVID-19 Micropore. Inc. located in Elkton. Maryland, is a manufacturer of reactive plastics which incorporate various powders into a molded matrix including products that are used as a C02 absorbent powder and formed into a cartridge to create an absorbent and life supporting system. Through the use of these proprietary technologies and ...
-
Thomas Kolaras Joins SERB and BTG Specialty Pharmaceuticals as US Chief Commercial Officer
SERB and BTG Specialty Pharmaceuticals are pleased to announce that Thomas Kolaras has been named the group’s new Chief Commercial Officer for its US business. Thomas is an accomplished commercial leader with more than 25 years of US and global experience across large and mid-sized biopharmaceutical companies. His career includes a wide range of roles in marketing, sales, operations, ...
-
SERB acquires the rights to Xermelo outside US and Japan for Carcinoid Syndrome Diarrhoea
SERB is pleased to announce it has acquired the rights from Ipsen to commercialize Xermelo® (telotristat ethyl) in Europe and other countries outside the US and Japan. Financial terms of the transaction were not disclosed. Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea (CSD) in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by ...
-
Ben Watt Joins SERB and BTG as Group CFO
SERB and BTG Specialty Pharmaceuticals are pleased to announce that Ben Watt has been named the group’s new Chief Financial Officer. Ben is an experienced CFO with a track record of building global finance teams and integrating business acquisitions. Ben most recently served as CFO of Crouzet, an independent manufacturer of electronic components used in heavily regulated industries. He ...
-
SERB receives EU approval for Voraxaze (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity
SERB and BTG Specialty Pharmaceuticals announced that the European Commission has granted marketing authorisation for Voraxaze (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity. Voraxaze is now authorized for marketing in all members states of the European Union ...
-
First Evidence of High-Dose Methotrexate Related Toxicity in Spain Presented at Virtual ISPOR Europe 2021
The first evidence of high dose methotrexate related toxicity (HDMTX) in Spain was presented today at Virtual ISPOR Europe 2021, a global conference on healthcare economics and outcomes. Xavier Badia, MD, MPH, PhD of Omakase Consulting S.L. presented the poster titled “Epidemiology and Clinical Management of Patients with Methotrexate Toxicity in Spain Using the Delphi Technique,” ...
-
SERB receives positive CHMP opinion for Voraxaze (glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity
SERB and BTG Specialty Pharmaceuticals today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorisation for Voraxaze (glucarpidase) to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you